SAN CARLOS, CA — Sift Biosciences is proud to announce that Dr. Yue Clare Lou, Co-Founder and CEO of Sift Biosciences, has been named to the Forbes 30 Under 30 list in Healthcare this year, recognizing her work in advancing next-generation peptide immunotherapies for cancer and autoimmune disease.
“I am honored to be recognized by Forbes in this year’s Healthcare 30 Under 30!” said Dr. Lou. “I’m grateful for this opportunity and excited to keep pushing boundaries with the goal of bringing life-changing therapeutics to patients.”
“I wanted to say THANK YOU to my co-founder Maddie Williams, who has been a champ in my startup journey. It’s been incredibly fun building Sift Biosciences together! I also wanted to say thank you to the Innovative Genomics Institute, the Women In Enterprising Science (WIES) committee, my PhD advisor Dr. Jill Banfield, my academic and industry mentors, and my friends and family. Thanks for supporting and believing in me — let’s keep rolling.”
About Sift Biosciences
Sift Biosciences is a preclinical immunotherapy company developing “T-cell booster” peptides designed to amplify immune responses in cancers and other immune diseases where current therapies fail. Founded in 2024 as a UC Berkeley spin-out, Sift combines AI, metagenomics, and high-throughput immune profiling to identify peptides capable of harnessing pre-existing immune memory for faster, safer, and more effective treatments. The company’s initial focus is on gastrointestinal and gynecologic cancers, with an expanding pipeline in autoimmunity.